Forecast & Rating5 analysts currently cover Hemab Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $61.20, about 24.5% upside from the current price of $49.16. Price targets are fairly clustered, pointing to relatively aligned views. For you, this means most professionals who study Hemab Therapeutics closely still see room for the stock to rise. Data as of Aug 11, 2026; for reference only and not investment advice.
Aug 11, 2026Price forecast
$61.2024.49%
Forecast & RatingStrong buy
5analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateAug 20, 2026
Forecast met86.9%
Stock price$49.16
Avg. target$61.2
High target$65
Low target$58
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.